Janssen Says FDA Approves Darzalex Combination Regimen in Multiple Myeloma

Date : 06/27/2019 @ 8:18PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 127.7  0.0 (0.00%) @ 12:19PM
Last Trade
Last $ 128.20 ▲ 0.50 (0.39%)

Janssen Says FDA Approves Darzalex Combination Regimen in Multiple Myeloma

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Johnson and Johnson Charts.

By Michael Dabaie


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said Thursday that the U.S. Food and Drug Administration approved Darzalex in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The approval is based on results from a Phase 3 clinical study, which showed the combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible, Janssen said.

This is the sixth Darzalex FDA-approved use in multiple myeloma and the second for newly diagnosed patients, the company said.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

June 27, 2019 15:03 ET (19:03 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.